Immediate effects of individualized heparin and protamine management on hemostatic activation and platelet function in adult patients undergoing cardiac surgery with tranexamic acid antifibrinolytic therapy
Restricted accessResearch articleFirst published online September, 2013
Immediate effects of individualized heparin and protamine management on hemostatic activation and platelet function in adult patients undergoing cardiac surgery with tranexamic acid antifibrinolytic therapy
This randomized prospective study was initiated to clarify whether individualized heparin and protamine dosing has immediate effects on hemostatic activation and platelet function in adult cardiac surgery.
Methods:
Sixty adults undergoing elective coronary artery bypass grafting (CABG) were assigned to receive individualized heparin and protamine (HMS group, n= 29) or a standard dose (ACT group, n=24). Measures of thrombin generation and Multiplate® (Verum Diagnostica, Munich, Germany) platelet function tests were performed before and after cardiopulmonary bypass (CPB).
Results:
HMS patients received higher heparin (p = 0.006) and lower protamine (p<0.001) doses. Post-CPB, HMS managed patients showed significantly lower thrombin generation (thrombin-antithrombin (TAT) p<0.02) than the ACT group. Moreover, HMS managed patients had a better preservation of platelet function (COL p = 0.013; ADP p = 0.04; TRAP p = 0.04).
Conclusion:
An individualized and stable heparin concentration and appropriate dosing of protamine can reduce thrombin generation and preserve platelet function, even in short-time CPB.
FergusonTBJr.HammillBGPetersonEDDeLongERGroverFL. A decade of change –risk profiles and outcomes for isolated coronary artery bypass grafting procedures, 1990–1999: a report from the STS National Database Committee and the Duke Clinical Research Institute. Society of Thoracic Surgeons. Ann Thorac Surg2002; 73: 480–489; discussion 489–490.
2.
FriedrichISimmAKottingJTholenFFischerBSilberRE. Cardiac surgery in the elderly patient. Dtsch Arztebl Int2009; 106: 416–422.
3.
KarkoutiKWijeysunderaDNYauTM. The independent association of massive blood loss with mortality in cardiac surgery. Transfusion2004; 44: 1453–1462.
4.
HattersleyPG. Activated coagulation time of whole blood. JAMA1966; 196: 436–440.
5.
BullBSHuseWMBrauerFSKorpmanRA. Heparin therapy during extracorporeal circulation. II. The use of a dose-response curve to individualize heparin and protamine dosage. J Thorac Cardiovasc Surg1975; 69: 685–689.
6.
HattersleyPG. Progress report: the activated coagulation time of whole blood (ACT). Am J Clin Pathol1976; 66: 899–904.
7.
BabkaRColbyCEl-EtrAPifarreR. Monitoring of intraoperative heparinization and blood loss following cardiopulmonary bypass surgery. J Thorac Cardiovasc Surg1977; 73: 780–782.
8.
CullifordATGitelSNStarrN. Lack of correlation between activated clotting time and plasma heparin during cardiopulmonary bypass. Ann Surg1981; 193: 105–111.
9.
DespotisGJGravleeGFilosKLevyJ. Anticoagulation monitoring during cardiac surgery: a review of current and emerging techniques. Anesthesiology1999; 91: 1122–1151.
10.
KosterAFischerTPrausM. Hemostatic activation and inflammatory response during cardiopulmonary bypass: impact of heparin management. Anesthesiology2002; 97: 837–841.
11.
KosterAHueblerSMerkleF. Heparin-level-based anticoagulation management during cardiopulmonary bypass: a pilot investigation on the effects of a half-dose aprotinin protocol on postoperative blood loss and hemostatic activation and inflammatory response. Anesth Analg2004; 98: 285–290, table of contents.
12.
GuzzettaNABajajTFazlollahT. A comparison of heparin management strategies in infants undergoing cardiopulmonary bypass. Anesth Analg2008; 106: 419–425, table of contents.
13.
KhanNUWayneCKBarkerJStrangT. The effects of protamine overdose on coagulation parameters as measured by the thrombelastograph. Eur J Anaesthesiol2010; 27: 624–627.
14.
AzizKAMasoodOHoschtitzkyJARonaldA. Does use of the Hepcon point-of-care coagulation monitor to optimise heparin and protamine dosage for cardiopulmonary bypass decrease bleeding and blood and blood product requirements in adult patients undergoing cardiac surgery?Interact Cardiovasc Thorac Surg2006; 5: 469–482.
15.
PappalardoFFrancoACrescenziGDe SimoneFTorraccaLZangrilloA. Anticoagulation management in patients undergoing open heart surgery by activated clotting time and whole blood heparin concentration. Perfusion2006; 21: 285–290.
16.
FitzgeraldDJPatelABodySCGarvinS. The relationship between heparin level and activated clotting time in the adult cardiac surgery population. Perfusion2009; 24: 93–96.
17.
GarvinSFitzGeraldDCDespotisGShekarPBodySC. Heparin concentration-based anticoagulation for cardiac surgery fails to reliably predict heparin bolus dose requirements. Anesth Analg2010; 111: 849–855.
Cross-Sectional Guidelines for Therapy with Blood Components and Plasma Derivates - 4th revised edition. Transfus Med Hemother2009; 36: 345–492.
20.
HoppeJDScribaPCKluterH. Cross-Sectional Guidelines for Therapy with Blood Components and Plasma Derivatives (4th revised edition, 2008) - Suspension of Chapter 5 ‘Human Albumin’. Transfus Med Hemother2011; 38: 71.
21.
Velik-SalchnerCMaierSInnerhoferP. An assessment of cardiopulmonary bypass-induced changes in platelet function using whole blood and classical light transmission aggregometry: the results of a pilot study. Anesth Analg2009; 108: 1747–1754.
22.
ShigetaOKojimaHHiramatsuY. Low-dose protamine based on heparin-protamine titration method reduces platelet dysfunction after cardiopulmonary bypass. J Thorac Cardiovasc Surg1999; 118: 354–360.
23.
SlaughterTFLeBleuTHDouglasJMJr.LeslieJBParkerJKGreenbergCS. Characterization of prothrombin activation during cardiac surgery by hemostatic molecular markers. Anesthesiology1994; 80: 520–526.
